Abstract 162P
Background
To evaluate clinical usefulness of hypofractionated radiotherapy (HRT) for pulmonary metastases from hepatocellular carcinoma (HCC) and investigate the prognostic factors affecting treatment outcome.
Methods
From March 2006 to May 2018, 58 patients with less than five pulmonary metastases from HCC who underwent HRT were analyzed retrospectively. Primary endpoint was treatment response rate. Secondary endpoints were progression-free survival, overall survival, prognostic factors affecting treatment outcomes and treatment-related side effects.
Results
The treatment response (complete and partial response) rate was 77.6 %, and the maximum treatment response was presented between 1 to 3 months after completion of HRT. The local control rate was 63.8 %. The median survival time was 16.3 months for all patients. The 1-year and 3-year overall survival rates were 79.3 % and 37.9 %, respectively. The median progression-free survival time was about 5 months and eighty-six percent of the patients (n = 50) showed post-treatment disease progression. Multivariate analysis identified the common prognostic factors for both OS and PFS as the planning target volume and maximal treatment response after HRT. The progression-free survival period was also a prognostic factor for OS in multivariate analysis. The grade 3 and 4 severe toxicities were reported in 4 and 3 patients, respectively.Table:
162P Prognostic factors
OS | PFS | |||||
---|---|---|---|---|---|---|
Median±SD* | p value† | Median±SD* | p value† | |||
Variable | (mo) | UVA | MVA | (mo) | UVA | MVA |
Age | 0.650 | 0.030 | 0.012 | |||
< 60 | 16.2±4.6 | 3.7±3.7 | ||||
≥ 60 | 21.4±7.9 | 4.9±1.3 | ||||
ECOG | 0.097 | 0.401 | ||||
0 | 44.3±17.2 | 8.0±3.0 | ||||
1, 2 | 16.3±4.5 | 3.7±1.3 | ||||
PTV size | 0.017 | 0.003 | 0.027 | 0.003 | ||
< 19 cc | 30.3±8.5 | 5.7±2.0 | ||||
≥ 19 cc | 11.5±2.1 | 3.0±0.3 | ||||
Type I max response | 0.013 | 0.000 | 0.029 | |||
CR+PR | 20.1±4.3 | 5.1±1.6 | ||||
SD+PD | 6.0±1.2 | 1.3±1.1 | ||||
Type II max response | 0.006 | 0.014 | 0.018 | |||
CR+PR+SD | 20.1±3.5 | 5.1±1.3 | ||||
PD | 4.6±1.8 | 1.2±0.1 | ||||
PFS period | 0.001 | 0.003 | ||||
< 5 mon | 10.6±3.5 | |||||
≥ 5 mon | 44.3±11.7 | |||||
Overall | 16.3±4.4 | 4.9±1.2 |
Conclusions
The considerable treatment outcome and acceptable toxicity may indicate clinical usefulness of HRT for patients who have less than five pulmonary metastases from HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract